QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines’ AYVAKIT® (avapritinib) in gastrointestinal stromal tumors
August 07, 2023 16:05 ET
|
QIAGEN N.V.
Venlo, the Netherlands, and Germantown, Maryland, Aug. 07, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. Food and Drug Administration (FDA)...
Bio-Rad and QIAGEN announce patent settlement and cross-licensing agreement
July 26, 2023 16:15 ET
|
QIAGEN N.V.
Hercules, Calif., and Venlo, the Netherlands, July 26, 2023 (GLOBE NEWSWIRE) -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today...
QIAGEN N.V. to release results for Q2 2023 and hold webcast
July 24, 2023 07:41 ET
|
QIAGEN N.V.
Venlo, The Netherlands, July 24, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the second quarter 2023. Press...
QIAGEN expands range of digital PCR kits and services for the biopharma industry
July 18, 2023 16:05 ET
|
QIAGEN N.V.
Venlo, the Netherlands, July 18, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the expansion of its digital PCR (dPCR) offering for the development of...
QIAGEN erweitert Angebot an digitalen PCR-Kits und -Dienstleistungen für Biopharma-Branche
July 18, 2023 16:05 ET
|
QIAGEN N.V.
Neue Partnerschaft mit Niba Labs ermöglicht Biopharma-Kunden Zugang zu Dienstleistungen für maßgeschneidertes digitales PCR-Testdesign // Neues CGT Viral Vector Lysis Kit bietet standardisierten...
FBI lässt NGS-basierten ForenSeq MainstAY Workflow von QIAGEN für das US-amerikanische National DNA Index System zu
June 20, 2023 16:05 ET
|
QIAGEN N.V.
Zulassung für National DNA Index System (NDIS) ermöglicht öffentlichen kriminaltechnischen Laboren mit Akkreditierung in den USA Zugang zu staatlichen Mitteln zur Einführung von...
FBI approves QIAGEN’s NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS)
June 20, 2023 16:05 ET
|
QIAGEN N.V.
NDIS approval provides access to federal government funding for accredited public crime laboratories in the U.S. to implement next-generation sequencing (NGS) for routine casework // NGS-based...
FBI approves QIAGEN’s NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS)
June 20, 2023 16:05 ET
|
QIAGEN N.V.
Venlo, the Netherlands, and San Diego, California, June 20, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that the U.S. Federal Bureau of Investigation...
QIAGEN provides reminder on settlement mechanics of 2023 and 2024 convertible notes
June 16, 2023 07:36 ET
|
QIAGEN N.V.
Venlo, the Netherlands, June 16, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a notice (reiterating its notice to holders dated January 9, 2019)...
QuantiFERON-TB Gold Plus von QIAGEN mit CD8-Technologie zeigt einzigartigen klinischen Nutzen in neuer Metaanalyse von Tuberkulose-Screenings
June 15, 2023 16:05 ET
|
QIAGEN N.V.
Erste systematische Auswertung zur klinischen Relevanz von Testwerten aus QuantiFERON-TB Gold Plus TB1- und TB2-Blutentnahmeröhrchen veröffentlicht // Studie mit 4.050 Versuchspersonen unterstreicht...